In the future, antigen delivery in the form of codon-optimized mRNAs or alternative delivery platforms for multivalent MSP2 and CSP formulations might be capable of eliciting immunity against dozens or even hundreds of circulating antigen variants of P. falciparum in a single vaccine shot imitating, in a way, the protection against clinical malaria conferred by repeated exposure to multiple infections. The gene discussed is DNAJC5; the disease is malaria.